+

US6963010B2 - Hydrophobic polyamine analogs and methods for their use - Google Patents

Hydrophobic polyamine analogs and methods for their use Download PDF

Info

Publication number
US6963010B2
US6963010B2 US10/296,259 US29625902A US6963010B2 US 6963010 B2 US6963010 B2 US 6963010B2 US 29625902 A US29625902 A US 29625902A US 6963010 B2 US6963010 B2 US 6963010B2
Authority
US
United States
Prior art keywords
polyamine
aliphatic
multiring
derivative
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased, expires
Application number
US10/296,259
Other languages
English (en)
Other versions
US20030187276A1 (en
Inventor
Mark R. Burns
Gerard F. Graminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aminex Therapeutics Inc
Original Assignee
MediQuest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MediQuest Therapeutics Inc filed Critical MediQuest Therapeutics Inc
Priority to US13/047,297 priority Critical patent/USRE43327E1/en
Priority to US10/296,259 priority patent/US6963010B2/en
Assigned to MEDIQUEST THERAPEUTICS, INC. reassignment MEDIQUEST THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAINDUR, NAND, GRAMINSKI, GERARD F., BURNS, MARK R.
Publication of US20030187276A1 publication Critical patent/US20030187276A1/en
Priority to US11/050,789 priority patent/US20050176828A1/en
Priority to US11/062,481 priority patent/US7432302B2/en
Application granted granted Critical
Publication of US6963010B2 publication Critical patent/US6963010B2/en
Assigned to AMINEX THERAPEUTICS, INC. reassignment AMINEX THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDIQUEST THERAPEUTICS, INC.
Adjusted expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Definitions

  • the invention in the field of chemistry and biochemistry relates to the synthesis and use of a novel class of polyamine transport inhibitor compounds. These compounds have pharmacological and/or agricultural applications as well as uses in analytical and preparative assays relating to polyamine transport. As pharmaceuticals, these compounds are used to treat disorders of undesired cell proliferation, especially in eukaryotic cells, alone or in combination with other agents such as polyamine synthesis inhibitors.
  • Polyamine transport into mammalian cells is energy and temperature dependent, saturable, carrier mediated and operates against a substantial concentration gradient (Seiler, N. et al. Polyamine transport in mammalian cells. Int. J. Biochem. 1990, 22, 211-218; Khan, N. A.; Quemener, V. et al. Characterization of polyamine transport pathways, in Neuropharmacology of Polyamines (Carter, C., ed.), 1994, Academic, San Diego, pp. 37-60). Ample experimental proof exists that polyamine concentration homeostasis is mediated via this transport system. Changes in the requirements for polyamines in response to growth stimulation is reflected by increases in the transport activity.
  • Intracellular putrescine deprivation induces uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone). Biochem. J. 1980, 192, 941-945). The cells then returned to their original rate of growth.
  • a radiochemical assay is used for biochemical analysis of transport and has been used to study polyamine transport in yeast and a variety of mammalian cells (Kakinuma, Y. et al., Biochem. Biophys. Res. Comm. 216:985-992, 1995; Seiler, N. et al., Int. J. Biochem. Cell Biol. 28:843-861, 1996). See, for example Huber, M. et al. Cancer Res. 55:934-943, 1995.
  • the present invention is directed to novel polyamine analogs and derivatives and methods for their use as drugs, as agricultural or as environmentally useful agents.
  • These novel polyamine analogs and derivatives comprise a hydrophobic moiety covalently attached to a polyamine moiety.
  • These novel PA analogs can be considered to have amphipathic character (hydrophobic as well as charged portions).
  • the polyamine analogs and derivatives of the invention include those that may be viewed as a polyamine acylated with a hydrophobic acyl group, where acylation is by formation of either an amide or a sulfonamide linkage. While the linkage between the hydrophobic acyl group and the polyamine moiety may occur at any amine group within the polyamine, linkages to a primary amine functionality are preferred.
  • the analogs and derivatives of the invention are potent inhibitors of cellular polyamine transport. Without being bound by theory, they are inferred to bind to a cell's polyamine transporter apparatus with very high affinity. They may be used independently or in combination with the inhibition of cellular polyamine synthesis, even in the presence of exogenously supplied spermidine, to inhibit cell growth and proliferation.
  • R is selected from H or from the group of a straight or branched C1-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted aliphatic; an aliphatic-substituted single or multiring aromatic; a single or multiring heterocyclic; a single or multiring heterocyclic aliphatic; a C1-10 alkyl; an aryl sulfonyl; or cyano;
  • X may be —CO—, —SO 2 —, or —CH 2 —, and
  • polyamine may be any naturally occurring, such as putrescine, spermine or spermidine, or synthetically produced polyamine.
  • R is at least about C5, at least about C10, at least about C11, at least about C12, at least about C13, at least about C14, at least about C15, at least about C16, at least about C17, at least about C18, at least about C19, at least about C20, or at least about C22.
  • the linkage between X and the polyamine may be direct, wherein there are no atoms between X and the nitrogen of the amine group of the polyamine, or indirect, where there may be one or more atoms between X and the nitrogen of the amine group of the polyamine.
  • the linkage between X and the polyamine may occur via any amino group within the polyamine, although a primary amino group is used in preferred embodiments of the invention.
  • the intervening one or more atoms are preferably those of an amino acid or a derivative thereof.
  • the intervening one or more atoms are those of lysine, aspartic acid, glutamic acid, omithine, or 2,4-diaminobutyric acid.
  • Preferred compounds of this type may be represented as R—X-L-polyamine
  • R is a straight or branched C10-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted or unsubstituted aliphatic; an aliphatic-substituted or unsubstituted single or multiring aromatic; a single or multiring heterocyclic; a single or multiring heterocyclic aliphatic; an aryl sulfonyl;
  • X is —CO—, —SO 2 —, or —CH 2 —;
  • L is a covalent bond or a naturally occurring amino acid, omithine, 2,4-diaminobutyric acid, or derivatives thereof.
  • the analogs and derivatives of the invention may be optionally further substituted at one or more other positions of the polyamine. These include, but are not limited to, internal nitrogen and/or internal carbon atoms.
  • preferred substituents are structures that increase polyamine transport inhibition, binding affinity or otherwise enhance the irreversibility of binding of the compound to a polyamine binding molecule, such as the polyamine transporter, an enzyme or DNA.
  • additional substituents include the aziridine group and various other aliphatic, aromatic, mixed aliphatic-aromatic, or heterocyclic multi-ring structures. Reactive moieties which, like aziridine, bind covalently to a polyamine transporter or another polyamine binding molecule, are also within the scope of this invention.
  • Such reactive moieties are used for affinity labeling in a diagnostic or research context, and may contribute to pharmacological activity in inhibiting polyamine transport or polyamine synthesis.
  • the reactive group can be a reactive photoaffinity group such as an azido or benzophenone group.
  • Chemical agents for photoaffinity labeling are well-known in the art (Flemming, S. A., Tetrahedron 1995, 51, 12479-12520).
  • a preferred aspect of the invention relates to a polyamine analog or derivative that is a highly specific polyamine transport inhibitor with pharmaceutical utility as an anti-cancer chemotherapeutic.
  • One class of a polyamine analog or derivative of the invention that binds to a polyamine-binding site of a molecule and/or inhibits polyamine transport, is described by the following formula II:
  • a, b, and c independently range from 1 to 10; d and e independently range from 0 to 30; each X is independently either a carbon (C) or sulfur (S) atom, and R 1 and R 2 are as described below, or each of R 1 X ⁇ O ⁇ n — and R 2 X ⁇ O ⁇ n — are independently replaced by H; and * denotes a chiral carbon position.
  • n is 1; if X is S, then n is 2; and if X is C, then the XO group may be CH 2 such that n is 0.
  • R 1 and R 2 are independently selected from H or from the group of a straight or branched C1-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted aliphatic; an aliphatic-substituted single or multiring aromatic; a single or multiring aromatic or saturated heterocyclic; a single or multiring heterocyclic aliphatic; a C1-10 alkyl; an aryl sulfonyl; or cyano.
  • heterocyclic rings as used herein include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, purine, quinoline, isoquinoline, and carbazole.
  • carboxyalkyl refers to the substituent —R′—COOH wherein R′ is alkylene; and carbalkoxyalkyl refers to —R′—COOR wherein R′ and R are alkylene and alkyl respectively.
  • alkyl refers to a saturated straight- or branched-chain hydrocarbyl radical of 1-6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 2-methylpentyl, n-hexyl, and so forth.
  • Alkylene is the same as alkyl except that the group is divalent.
  • Aryl or alkyl sulfonyl moieties have the formula —SO 2 R, and alkoxy moieties have the formula —O—R, wherein R is alkyl, as defined above, or is aryl wherein aryl is phenyl, optionally substituted with 1-3 substituents independently selected from halo (fluoro, chloro, bromo or iodo), lower alkyl (1-6C) and lower alkoxy (1-6C).
  • polyamine analog or derivative of the invention that binds to a polyamine-binding site of a molecule and/or inhibits polyamine transport, is described by the following formula III: wherein a, b, and c independently range from 1 to 10 and d and e independently range from 0 to 30.
  • R 1 and R 2 are defined as above for formula II and R 3 and R 4 are independently selected from organic substituents including —CH 3 and as defined above for R 1 and R 2 in formula II above.
  • This grouping of analogs is produced by reductive amination of the free amino precursor with a ketone. Some members of this group of analogs are shown in Series V (see FIG. 2 ).
  • R 1 and R 2 are identical and as described for formula II. Positions R 3 and R 4 may also be identical, and all of R 1 through R 4 may also be identical. Additionally, each of positions R 1 , R 2 , R 3 and R 4 in formula III may also be independently H.
  • proximal and/or the distal amino group relative to the polyamine can be di-alkylated to form tertiary amines.
  • These materials can be synthesized by reductive amination with a large excess of the carbonyl component. Additionally, these materials may be produced by a conjugate addition of the amine precursor to an ⁇ , ⁇ -unsaturated carbonyl or ⁇ , ⁇ -unsaturated nitrile.
  • R 1 , R 2 , R 3 and R 4 can be independently varied and are as defined as above for formula III.
  • R 1 , R 2 , R 3 and R 4 may also be independently H.
  • the values of a, b, c, d and e are as described above for formula III. This aspect of the invention is depicted in the following formula IV:
  • Z 1 is NR 1 R 3 and Z 2 is selected from —R 1 , —CHR 1 R 2 or —CR 1 R 2 R 3 (wherein R 1 , R 2 , and R 3 are as defined above for formula III) or Z 2 is NR 2 R 4 and Z 1 is selected from —R 1 , —CHR 1 R 2 or —CR 1 R 2 R 3 (wherein R 1 , R 2 , and R 3 are as defined above for formula III)
  • Values for a, b, and c independently range from 1 to 10; d and e independently range from 0 to 30.
  • Compounds encompassed by formula V may be prepared by first coupling amino acid derivatives (modified to contain the non-amine containing Z group) to a polyamine followed by appropriate derivatization of the amine containing Z group. Chemistries for such reactions are known in the art and disclosed herein.
  • positions R 1 , R 2 , R 3 and R 4 of all the formulas set forth above are independently selected from the following, where each of g, h, i, j, and k are independently selected from 0 to 15: wherein E refers to “entadel” and Z refers to “zusammen”.
  • the present invention includes the free base or acid forms, as well as salts thereof, of the polyamine analogs and derivatives described by the above formulas.
  • the invention also includes the optical isomers of the above described analogs and derivatives, especially those resulting from the chiral center indicated above with a *.
  • mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are encompassed.
  • the invention also provides prodrug forms of the above described analogs and derivatives, wherein the prodrug is metabolized in vivo to produce an analog or derivative as set forth above. Indeed, some of the above described analogs or derivatives may be a prodrug for another analog or derivative.
  • compositions containing the above described analogs and derivatives are provided.
  • the compositions are formulated to be suitable for pharmaceutical or agricultural use by the inclusion of appropriate carriers or excipients.
  • methods for the use of the above described analogs and derivatives, as well as compositions are provided. These methods include uses of the invention's polyamine compounds to inhibit polyamine transport, as well as treat human and agricultural diseases and conditions.
  • human diseases and conditions include, but are not limited to, cancer, osteoporosis, asthma, autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus, Type I insulin-dependent diabetes, tissue transplantation, African sleeping sickness, psoriasis, restenosis, inhibition of unwanted hair growth as cosmetic suppression, hyperparathyroidism, inflammation, treatment of peptic ulcer, glaucoma, Alzheimer's disease, suppression of atrial tachycardias, stimulation or inhibition of intestinal motility, Crohn's disease and other inflammatory bowel diseases, high blood pressure (vasodilation), stroke, epilepsy, anxiety, neurodegenerative diseases, hyperalgesic states, protection against hearing loss (especially cancer chemotherapy induced hearing loss), and pharmac
  • FIGS. 1A and 1B show Scheme 1, a pathway for the synthesis of selectively acylated lysine-spermine derivatives.
  • the pathway may be readily adapted for the synthesis of other polyamine derivatives by the use of an analogous protected “NH—X—COO” starting material (wherein X is CH—(CH 2 ) d —NH—COO—CH 2 —Ph, wherein d is as described above and “Ph” is phenyl) and/or the use of any primary polyamine, including spermine.
  • FIGS. 2A-2X illustrate exemplary polyamine structures encompassed by the present invention. They have been divided into Series I-VI based upon the character of the chemical moiety attached to a spermine backbone to produce exemplary analogs and derivatives of the invention. Other polyamines may also be used as the backbone.
  • the structures depicted in the first, left-most column of each table represent the specific chemical starting materials utilized in the synthesis of individual polyamine structures.
  • the synthetic steps used result in the end products that are carboxamides from a reaction between an acyl chloride and an amine (series I), sulfonamides from the reaction between a sulfonyl chloride and an amine (series II), carboxamides from the reaction of a DCC, HBTU or PyBOP activated carboxylic acid and an amine (series III), alkylated secondary amines from the reductive amination of the amine with an aldehyde (series IV), alkylated secondary amines with ⁇ -alkyl substituents from the reductive amination of the free amino precursor with a ketone (Series V) and di-alkylated tertiary amine products by reductive amination with a large excess of a carbonyl containing (e.g.
  • Series VI aldehyde or ketone component
  • Columns E and F are directed to doubly derivatized forms of the base chemical structure.
  • FIGS. 3A and 3B show representative structures of polyamine analogs relating to the present invention.
  • FIG. 4 shows the relationship between the length of the hydrocarbon substituent at the ⁇ -position of the L-lysine analogs and the resulting activity as polyamine transport inhibitors as defined by EC 50 (see Example IV).
  • FIG. 5 representatively shows the portion of compounds for calculation of logP values.
  • FIG. 6 presents calculated logP values versus HPLC retention time for dansylated derivatives of compounds shown in FIG. 2 (Series I).
  • FIG. 7 presents calculated logP values versus average EC 50 values obtained for compounds with 4 cell lines (data for Series I compounds in Table 1).
  • FIG. 8 presents HPLC retention time for dansylated derivatives of compounds shown in Table 2 (Series IV and V) versus average EC 50 values obtained for 4 cell lines (data in Table 1).
  • FIG. 9 shows the relationship between calculated logP values and HPLC retention time for dansylated derivatives of compounds shown in Table 2 (Series IV and V).
  • FIG. 10 presents calculated logP values versus average EC 50 values obtained for compounds with 4 cell lines (data for Series IV and V compounds in Table 2).
  • FIG. 11 presents HPLC retention time for dansylated derivatives of compounds shown in Table 2 (Series IV and V) versus average EC 50 values obtained for 4 cell lines using data in Table 1.
  • FIGS. 12A-12K show the structures of exemplary polyamine analogs and derivatives of the present invention.
  • the present inventors have designed novel polyamine analogs and derivatives for the inhibition of polyamine transport and other uses. These analogs and derivatives are inferred to bind polyamine transporters with high affinity and inhibit polyamine transport, either competitively or non-competitively. Thus these compounds can alter polyamine metabolism in cells by reducing or preventing polyamine uptake.
  • one or more polyamine analogs and derivatives are used in combination with polyamine synthesis inhibitors to inhibit cell growth and proliferation.
  • they are useful as drugs in a number of diseases, particularly cancer and other conditions involving cellular proliferation, including, but not limited to, inflammatory diseases or conditions where components of the immune system undergo undesired proliferation.
  • Non-limiting examples include asthma, autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus, Type I insulin dependent diabetes, psoriasis, restenosis, inhibition of unwanted proliferation of hair on skin, tissue transplantation, African sleeping sickness, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, suppression of atrial tachycardias, stimulation or inhibition of intestinal motility, Crohn's disease and other inflammatory bowel diseases, high blood pressure (vasodilation), stroke, epilepsy, anxiety, neurodegenerative diseases, hyperalgesic states, the protection of hair cells from chemotherapy induced loss of hearing, and pharmacological manipulation of cocaine reinforcement and craving in treating cocaine addiction and overdose, and other fungal, bacterial, viral, and parasitic diseases.
  • polyamine includes putrescine, spermine or spermidine, as well as longer linear polyamines, branched polyamines, and the like, which may have between 2 and about 10 nitrogens. Also included in this definition are polyamine derivatives or analogs comprising a basic polyamine chain with any of a number of functional groups bound to a C atom or a terminal or internal N atom. For modification at a primary amino group, a polyamine must, of course, contain such a group.
  • Polyamine “analogs” and/or “derivatives” generally refer to any modified polyamine molecule disclosed or described herein. These molecules are generally modifications of existing polyamines, whether naturally occurring or synthetically produced, and may also be referred to as “polyamine agents”, “PA” or “agents” of the invention. Preferred PAs bind and/or inhibit cellular polyamine transport, and as such may also be referred to as “transport binding molecules” or “polyamine transport inhibitors”.
  • the scope of this definition includes any modification to produce a PA from an existing polyamine or the isolation of a structurally identical PA from a naturally occurring source. Preferably, the modification is the addition of one or more chemical moieties to the polyamine.
  • a PA that is an “inhibitor” polyamine analog or derivative (a) binds to polyamine transporters better than a native polyamine and/or (b) by some means blocks the uptake of a polyamine into a cell or a subcellular polyamine transporter preparation.
  • the invention includes PAs that efficiently inhibit polyamine transporters in different eukaryotic cell types as well as inhibit cellular growth and proliferation when used in combination with a polyamine synthesis inhibitor.
  • the PAs of the invention generally have an acylated primary amine functionality and are expected to bind to a cell's polyamine transporter apparatus with a very high affinity. Measurements of K i were determined by using an assay that shows the inhibition of polyamine uptake, such as uptake of 3 H-spermidine.
  • the PAs were also analyzed with a secondary assay to show inhibition of cellular polyamine uptake based on a measurement of cellular growth inhibition in combination with a potent inhibitor of polyamine biosynthesis.
  • This assay was conducted in the presence of polyamines, such as spermidine, to determine a PA's ability to prevent the uptake of polyamines thereby overcoming the polyamine biosynthesis inhibition with DFMO (difluoromethylomithine). Due to the trend that polyamine mono-anides give high potency in both of these assays, it has been inferred, without limiting the invention thereto, that there is a site on the transporter protein for tight binding of the inhibitor's amide functionality.
  • DFMO difluoromethylomithine
  • Preferred embodiments of these PAs are the result of acylation at a polyamine molecule with two or more primary amine groups.
  • the linkage between the acyl group and the primary amine group is preferably an amide linkage (indicated below as the bond between “CO” and “NH”) and results in a molecule with the following general formula. rest of acyl group-CO—NH-rest of polyamine
  • polyamine in the above formula may be any polyamine with at least one primary amine group, but more preferably with two or more primary groups, for linkage to the acyl group.
  • One preferred class of acyl groups for inclusion in the above formula contains two primary amines for further acylation.
  • the resultant class of PAs may be described by the following formula (formula II).
  • Non-limiting examples of alkyl moieties as present in these compounds include straight or branched chains of at least about 8 carbon atoms for increased hydrophobicity (or lipophilicity), such as at least about 10, at least about 12, at least about 14, at least about 16, at least about 18, at least about 20, at least about 22, at least about 24, at least about 26, at least about 28, and at least about 30.
  • the chain is of at least about 19, 21, 23, 25, or 27 carbon atoms, with at least about 20 to at least about 24 or 26 as even more preferred.
  • PAs encompassed by the above formula is where d is 4 and e is 0, although generally excluded from this group are PAs where R 2 X ⁇ O ⁇ n — is an H and R 1 X ⁇ O ⁇ n — is R 1 SO 2 — wherein R 1 is a thiophene moiety linked to the S atom via the 2 position, and substituted at the 5 position, of the thiophene.
  • R 1 is a thiophene moiety linked to the S atom via the 2 position, and substituted at the 5 position, of the thiophene.
  • the substitution at the 5 position includes an amide linkage.
  • PAs wherein the amide linkage is attached to a chlorinated aromatic group, such as the compound identified as ORI 1340 in U.S. patent application Ser. No. 09/396,523, filed Sep. 15, 1999.
  • the invention includes, but is not limited to, situations where the hydrophobic (lipophilic) moiety may serve as an anchor to some hydrophobic pocket on the transporter or in a region nearby. This may result in the interaction of the polyamine portion of the analog with the polyamine transporter.
  • the logP coefficient is the logarithm of the ratio of distribution of a compound in a mixture of 1-octanol and H 2 O.
  • Compounds with logP values greater than 1 are considered lipophilic (greater solubility in 1-octanol versus H 2 O).
  • the presence of ionizable groups in the compound has a dramatic effect on this parameter. Ionization will greatly increase a compound's H 2 O solubility. For this reason, a compound's ionization potential must be taken into consideration when correlating lipophilicity with activity.
  • One such computer program is ChemDraw Pro Version 5.0 from CambridgeSoftCorporation.
  • Preferred PAs of the invention with respect to Series I type compounds are those with low EC 50 values, such as those with below about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20 or about 25 minute HPLC retention times.
  • Preferred PAs of the invention with respect to Series IV and V type compounds are those with low EC 50 values, such as those with below about 5, about 6, about 7, about 8, about 9, about 10, about 12, about 14, about 16, about 18, or about 20 minute HPLC retention times.
  • the present invention utilized a dansylation protocol to form dansyl derivatives of the described analogs and analyzing these derivatives by fluorescence detection on C18 reverse phase HPLC. The difference between the elution of the peak due to the analog and the peak due to an internal standard (1,7-diaminoheptane) is shown for several representative analogs in Tables 1 and 2 above.
  • the side chains for the twenty naturally occurring amino acids span a range of free energy values for the transfer from the vapor phase to H 2 O from 2.39 kcal/mol for hydrogen (glycine) or 1.94 kcal/mol for methane (alanine) to ⁇ 7.00 kcal/mol for n-butylamine (lysine) or ⁇ 14.6 kcal/mol for n-propylguanidine (arginine).
  • hydrophilic potential scale which is correlated with the potential that a given amino acid would be present on the outside, or hydrophilic portion of a protein versus the more hydrophobic interior of a protein.
  • the authors state “that the energetic cost of removing hydrophilic side chains from water is much greater than the cost of pulling hydrophobic side chains into water, and, indeed, it has been observed that hydrophobic residues occur rather often at the surfaces of proteins.”
  • the present invention could use this scale to describe the lipophilicity of the substituent attached to the polyamine.
  • the polyamine portion is removed before this analysis.
  • any substituent with a free energy of transfer from the vapor phase to H 2 O less than that determined for n-butylamine (and thus correlated to lysine) of ⁇ 7.00 kcal/mol would be expected to be a preferred polyamine transport inhibitor in comparison to the lysine-spermine conjugate (ORI 1202).
  • PAs wherein d is 4 and e is 0 includes both the L and D-stereoisomers due to the chiral carbon indicated by * in the above formula.
  • Exemplary PAs such as ORI 1202 (L-Lys-spm), 1426 (D-Lys-spm), and those containing IA4 ( FIG. 2 ) demonstrated potency in both the transporter inhibition and cell growth inhibition assays described below.
  • PA ORI 1202 also displayed effectiveness in several anti-cancer mouse xenograft models. See Weeks, R. S., Vanderwerf, S. M., Carlson, C. L., Burns, M. R., O'Day, C. L., Cai, C. F., Devens, B.
  • increases in the lipophilicity of the substituent at the above R 1 and R 2 positions may dramatically increase the affinity for the polyamine transporter.
  • Increases in lipophilicity in the PAs of the invention may improve the inhibition of polyamine transport due to the presence of both hydrophilic and hydrophobic domains.
  • Biological systems have a significant chemical problem when they attempt to move a very hydrophilic substance, such as polycationic polyamines, across their very hydrophobic outer membrane barriers. If the transporter moves the polyamines in their polycationic forms across this barrier, the transporter may do so via some mechanism for masking or minimizing their hydrophilicity.
  • Mechanisms for this may include the formation of specific salt bridges between the polyamine and negatively charged residues on the protein or formation of a charged interior in the intermembrane pore.
  • the transporter may have the task of providing a very specific polyamine shaped hydrophilic pore in the presence of the very hydrophobic environment of the membrane. For these reasons the transporter likely has hydrophobic residues for interactions with the membrane in close proximity to hydrophilic residues specific for interactions with the polyamine.
  • the present invention exploits the likely characteristics of a polyamine transporter to improve transport inhibition.
  • the present invention provides several series of PAs that contain both a polyamine-mimicking portion and a hydrophobic membrane-mimicking portion. These PAs have been inferred to have great affinity for the transporter, and they show substantially increased growth inhibition (in combination with a polyamine synthesis inhibitor) in comparison to PAs lacking a significantly hydrophobic domain. Possibly for very similar reasons, the present PAs are also expected to show improved bioavailability through oral administration. Increases in lipophilicity are expected to enhance absorption after oral uptake.
  • FIG. 4 shows the relationship between the length of the hydrocarbon substituent at the R position and the resulting EC 50 value in the presence of a polyamine synthesis inhibitor.
  • Table 3 shows the results from analysis of various exemplary PAs for their ability to inhibit cellular growth in combination with DFMO relative to control cells left untreated.
  • EC 50 refers to the concentration of PA resulting in 50% of maximum cell growth inhibition in the presence of both DFMO and the PA.
  • K i refers to the inhibition constant for polyamine transport based on double reciprocal Lineweaver-Burke plot analyses of four radioactive substrate concentrations (0.3-3 ⁇ M) and five inhibitor concentrations (0.01-1.0 ⁇ M) and a control.
  • Compounds ORI 1202 and 1426 are included for comparison. See the Examples below.
  • EC 50 values ( ⁇ M) of representative polyamine analogs determined in the presence of DFMO (1-5 mM). Also shown are the IC 50 results from analyses of various exemplary PAs. IC 50 refers to the concentration of PA that results in 50% of maximum cell growth inhibition in the presence of PA alone. Cell Line EC 50 ( ⁇ M) AVG.
  • FIG. 2 A set of PAs wherein positions R 1 and R 2 of formula I are substituted by an aliphatic chain with varying degrees of unsaturation in the hydrocarbon chain are represented in FIG. 2 , Series III. These compounds include those with internal geometrically cis (zusammen or Z-form) and trans (entitch or E-form) isomers are also presented in this series.
  • the invention incorporates considerations based on the charge character of the PA.
  • the introduction of the R 1 X ⁇ O ⁇ n — and R 2 X ⁇ O ⁇ n — moieties reduces the number of positive charges in the analog or derivative by one.
  • the vast majority of amine groups will be in their positively charged ammonium state.
  • PAs based on the long-chain hydrocarbon containing carboamides ( FIG. 2 , Series I), may be prepared by incorporating the lipophilic and biologically stable sulfonamide group. These PAs are shown in FIG. 2 , Series II. Without being bound by theory, it may be that the addition of an additional carbonyl-like oxygen atom in the sulfonamide series increases the interactions at an amide-binding domain of polyamine transporters. An additional factor which may be playing a role is the increased lipophilicity in sulfonamides versus carboxamides. Additionally sulfonamides are known to be more biologically stable in comparison to carboxamides.
  • the present invention also provides additional ways to increase the lipophilicity of the substituents on the PA molecule.
  • Alternatives with additional alkyl groups on the acyl portion of the molecule will increase the lipophilicity of this group and thus give an analog with higher activity.
  • One additional method to increase this lipophilicity is through attachment of an additional alkyl chain alpha to the amino group (substituent which is attached to the carbon atom attached to the nitrogen). These analogs are produced by reductive amination of the free amino precursor with one of the ketone reagents shown in Series V.
  • An additional advantage provided by inclusion of a methyl, or other substituent, at the alpha position of the amine group is decreased rate of biological metabolism.
  • An additional method to increase the lipophilicity of the analogs is through the production of a tertiary amine at the proximal or distal, or both, nitrogen atoms of the molecule.
  • These molecules which are shown in Series VI, are produced via the reductive amination reaction using a free mono- or di-amine precursor and an excess of the carbonyl containing reagent shown in Series VI.
  • An alternative method to produce these di-substituted tertiary amine containing molecules is the conjugate addition of the selectively protected amine precursor to an ⁇ , ⁇ -unsaturated carbonyl compound or an ⁇ , ⁇ -unsaturated nitrile compound.
  • the present invention further provides methods for the synthesis of the disclosed PAs.
  • an orthogonally protected diamine containing compound such as, but not limited to, certain amino acids, is coupled to a primary amine group of a polyamine followed by deprotection of one or both of the protected amine groups followed optionally by further derivatization of the amine.
  • an exemplary scheme for the production of spermine based PAs according to the above formula wherein d is 4, e is 0, X is C, and either R 1 X ⁇ O ⁇ n — or R 2 X ⁇ O ⁇ n — is H is shown in FIG.
  • Any appropriate protecting group(s) may be used in the practice of the invention, and the indication of Boc-(butoxycarbonyl-) and Cbz-(carbobenzoxy-) protecting groups are for illustrative purposes only.
  • Other protective group strategies are known in the art (see, for example, “Protective Groups in Organic Synthesis—Third Ed. 1999, eds. T. W. Greene and P. G. M. Wuts. John Wiley and Sons, Inc. New York).
  • polyamine analogs may be prepared via the coupling of distal carboxylic acid containing amino acids with suitable protecting groups on this distal carboxylic acid (e.g. methyl or benzyl ester) such as N- t Boc-Asp(OCH 3 )—OH or N- t Boc-Glu(OCH 3 )—OH with a primary amine group of a polyamine (such as, but not limited to, spermine) followed by exhaustive protection of the remaining amino groups. After purification by silica gel chromatography the distal carboxylic acid is deprotected and reacted with long chain hydrocarbon containing amines or alcohols to give amides or esters respectively.
  • suitable protecting groups on this distal carboxylic acid e.g. methyl or benzyl ester
  • suitable protecting groups on this distal carboxylic acid e.g. methyl or benzyl ester
  • suitable protecting groups on this distal carboxylic acid e.g. methyl or benzyl ester
  • n can also be greater than 2, preferably up to about 10 (including 3, 4, 5, 6, 7, 8 and 9) and R is defined as provided for R 1 and R 2 in formula II above.
  • the alpha amino group of the distal carboxylic acid containing amino acid may also be derivatized as described above in Formula II. Such compounds may be described as “inverted” amide or ester derivatives of the compounds described in FIG. 2 .
  • Similar hydrophobic PAs can be prepared by the use of cysteine, serine, or homo serine to link the hydrophobic and polyamine moieties indirectly.
  • the hydrophobic PAs may also be linked via an ester linkage (like that possible via serine), a thioester linkage (like that possible via cysteine), a urea linkage (—N—CO—N—), a carbamate linkage (—O—CO—N— or —N—CO—O—), or an extended sulfonamide linkage (—NH—SO 2 —),
  • the active ester is added to an excess of polyamine to produce a mixture of substituted and unsubstituted acyl polyamines.
  • the remaining free amino groups of the polyamines can then be protected, such as via their t Boc or Cbz carbamates, and the desired orthogonally-protected products can be isolated. Full protection of the amino groups produces a more lipophilic product mixture which facilitates purification of the desired compound.
  • the exemplary reaction scheme in FIG. 1 results in two synthetic intermediates, one with 4 Boc and 1 Cbz carbamates and the other with 4 Cbz and 1 Boc carbamates.
  • the deprotected amino groups may then be further modified via conventional amide chemistry.
  • the deprotected amino groups may be acylated or alkylated with either an acyl chloride or sulfonyl chloride to produce PAs shown in FIG. 2 as Series I and II, respectively.
  • the positions may also be carboxylic acid activated with standard peptide coupling reagents such as DCC, PyPOP or HBTU (to produce Series III PAs) or aldehydes using reductive amination conditions (to produce Series IV PAs). Additional analogs are produced by reductive amination of the free amino precursor with one of the ketone reagents shown in Series V.
  • Series VI analogs are produced via the reductive amination reaction using a free mono- or di-amine precursor and an excess of the carbonyl containing reagent shown in the Series VI portion of FIG. 2 .
  • An alternative method to produce these di-substituted tertiary amine-containing molecules is the conjugate addition of the selectively protected amine precursor to an ⁇ , ⁇ -unsaturated carbonyl compound or an ⁇ , ⁇ -unsaturated nitrile compound.
  • the above described synthetic schemes may be conducted in a parallel fashion to permit the simultaneous production of multiple PAs.
  • the reaction scheme shown in FIG. 1 may be started with a mixture of L- and D-forms of Boc-Lys-(Cbz)-ONP and spermine. This results in a possible 4 different amino groups (two based on each of the L- and D-forms, and two based on each of the distal and proximal amino groups) deprotection and subsequent modification. There are also two additional possible modifications where both amino groups are simultaneously deprotected for subsequent modification. This results in a total of 6 possible routes for modification.
  • compositions containing one or more PAs, as well as acceptable salts thereof, in combination with an excipient, diluent or vehicle to facilitate its use or administration to a subject Preferably, the compositions are formulated for pharmaceutical, therapeutic or agricultural uses.
  • Pharmaceutically acceptable salts of the invention (which contain basic groups) are formed where appropriate with strong or moderately strong, non-toxic, organic or inorganic acids in the presence of the basic amine by methods known in the art.
  • Exemplary salts include, but are not limited to, maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate and nitrate salts.
  • the PAs of the invention possess the ability to inhibit polyamine transport, a property that is exploited in the treatment of any of a number of diseases or conditions, most notably cancer.
  • a composition of this invention may be active per se, or may act as a “pro-drug” that is converted in vivo to active form.
  • PAs of the invention may be incorporated into convenient dosage forms, such as capsules, impregnated wafers, tablets or injectable preparations. Solid or liquid pharmaceutically acceptable carriers may also be employed. Pharmaceutical compositions designed for timed or delayed release may also be formulated.
  • compositions contain anti-oxidants, surfactants and/or glycerides.
  • anti-oxidants include, but not limited to, BHT, vitamin E and/or C.
  • glycerides include, but are not limited to, one or more selected from acetylated or unsubstituted monoglycerides; medium chain triglycerides, such as those found in oils; and caprylocaproyl macrogol-8 glycerides.
  • the compounds of the invention are administered systemically, e.g., by injection or oral administration.
  • injection may be by any known route, preferably intravenous, subcutaneous, intramuscular, intracranial or intraperitoneal.
  • injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
  • Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.
  • the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, liquid containing capsule, sterile injectable liquid (e.g., a solution), such as an ampule, or an aqueous or nonaqueous liquid suspension.
  • the pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral or parenteral administration.
  • Other preparations for topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration may also be prepared.
  • the pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.
  • the pharmaceutical composition may be administered topically or transdermally, e.g., as an ointment, cream or gel; orally; rectally; e.g., as a suppository, parenterally, by injection or continuously by infusion; intravaginally; intranasally; intrabronchially; intracranially; intraaurally; or intraocularly.
  • Intraaural formulations are particularly preferred for the treatment or alleviation of hearing loss due to chemotherapy.
  • the compound may be incorporated into topically applied vehicles such as a salve or ointment.
  • the carrier for the active ingredient may be either in sprayable or nonsprayable form.
  • Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water.
  • Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like.
  • auxiliary agents e.g., preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like.
  • Preferred vehicles for non-sprayable topical preparations include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000); conventional creams; gels; as well as petroleum jelly and the like.
  • Topical preparations are particularly preferred for the application of the present invention to the control of unwanted hair growth on skin.
  • sprayable aerosol preparations wherein the compound, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant.
  • the aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the compounds of the invention.
  • a target area e.g., skin surface, mucous membrane, eyes, etc.
  • This amount will generally range from about 0.001 mg to about 1 g per application, depending upon the area to be treated, the severity of the symptoms, and the nature of the topical vehicle employed.
  • compositions of the invention may be administered alone or in combination with one or more additional compounds that are used to treat the disease or condition.
  • the PAs are given in combination with anti-tumor agents, such as mitotic inhibitors, e.g., vinblastine; alkylating agents, e.g., cyclophosphamide; folate inhibitors, e.g., methotrexate, pritrexim or trimetrexate; antimetabolites, e.g., 5-fluorouracil and cytosine arabinoside; intercalating antibiotics, e.g., adriamycin and bleomycin; enzymes or enzyme inhibitors, e.g., asparaginase; topoisomerase inhibitors, e.g., etoposide; or biological response modifiers, e.g., interferon and interleukin-2.
  • pharmaceutical compositions comprising any known cancer therapeutic in combination with the PAs disclosed herein are within the scope of this invention.
  • the present compounds are administered in combination with one or more polyamine synthesis inhibitors such as, but not limited to, inhibitors of ornithine decarboxylase such as DFMO, aceylenic putrescine, 1-aminooxy-3-aminopropane, antizyme, 2-butylputrescine, cadaverine, L-canaline, 5′-deoxy-5′-[N-methyl-N-[3-(aminooxy)ethyl]amino]adenosine, 5′-deoxy-5′-[N-methyl-N-[3-(hydrazinopropyl)amino]adenosine, diaminopropane, 1,3-diamino-2-propanol, 2-difluoromethyl putrescine, difluorophenylethyl(4-aminopropylamidinohydrazone), 2,3-dimethylputrescine, N-dimethylputrescine, 2-
  • SAM486A 4-aminoindanon-1-(2′amidino)hydrazone dihydrochloride monohydrate
  • S-adenosyl-1,8-diamino-3-thiooctane S-(5′-adenosyl)methylthio-2-aminooxyethan, S-adenosyl-3-methylthio-1-propylamine
  • 5′- ⁇ [(Z)-4-amino-2-butenyl]methylamino ⁇ -5′-deoxyadenosine 5′-amino-5′-deoxyadenosine
  • 5′-[(aminoiminomethyl)amino]-5′]deoxyadenosine dihydrogensulphate 1-aminooxy-3-aminopropane
  • the PAs of the invention may also be used in combination with monoclonal antibodies and tumor vaccines as well as with cellular therapy in subjects undergoing treatment for human diseases such as cancer.
  • the PAs may also be used for chemoprevention in subjects at risk for developing cancer wherein one or more PAs are taken alone or in combination with a polyamine synthesis inhibitor to prevent the onset or recurrence of cancer.
  • compositions of the invention may also comprise one or more other medicaments such as anti-infectives including antibacterial, anti-fungal, anti-parasitic, anti-viral, and anti-coccidial agents.
  • anti-infectives including antibacterial, anti-fungal, anti-parasitic, anti-viral, and anti-coccidial agents.
  • Typical single dosages of the compounds of this invention are between about 1 ng and about 10 g/kg body weight.
  • the dose is preferably between about 0.01 mg and about 1 g/kg body wt. and, most preferably, between about 0.1 mg and about 100 mg/kg body wt.
  • dosages in the range of about 0.01-20% concentration of the compound, preferably 1-5% are suggested.
  • a total daily dosage in the range of about 1-500 mg is preferred for oral administration.
  • the foregoing ranges are, however, suggestive, as the number of variables in regard to an individual treatment regime is large, and considerable excursions from these recommended values are expected and may be routinely made by those skilled in the art.
  • Effective amounts or doses of the compound for treating a disease or condition can be determined using recognized in vitro systems or in vivo animal models for the particular disease or condition.
  • many art-recognized models are known and are representative of a broad spectrum of human tumors.
  • the compounds may be tested for inhibition of tumor cell growth in culture using standard assays with any of a multitude of tumor cell lines of human or nonhuman animal origin. Many of these approaches, including animal models, are described in detail in Geran, R. I. et al., “Protocols for Screening Chemical Agents and Natural Products against Animal Tumors and Other Biological Systems (Third Edition)”, Canc. Chemother. Reports , Part 3, 3:1-112.
  • the present invention also provides methods of using the PAs, whether formulated in compositions or not, to inhibit cell growth and proliferation when used alone or in combination with a polyamine synthesis inhibitor. Such methods may be readily conducted by systemic or local administration of the PAs. Local delivery of a PA provides a high local concentration while reducing the likelihood of systemic effects on polyamine metabolism that may result from systemic PA administration.
  • the inhibition of cellular growth and proliferation is advantageously conducted with the contemporaneous administration of one or more inhibitors of polyamine synthesis.
  • Such inhibition may be applied toward a variety of cell types, including, but not limited to, bacterial cells, fungal cells, and the eukaryotic cells of higher multicellular organisms.
  • one or more PAs may be used to inhibit bacterial or fungal cell growth. This embodiment may be advantageously used in both the clinic and agriculture to control bacteria or fungi.
  • one or more PAs may be used in combination with an inhibitor of polyamine synthesis to inhibit the growth and/or proliferation of cancer cells, including those of solid tumors. While this latter application may be performed in any multicellular organism, most preferred are applications of the invention for use in human subjects.
  • a PA may be used to identify and/or localize a polyamine transporter by virtue of physical binding between the PA and the transporter and the presence of a label linked to the PA.
  • Suitable labels are well known in the art, and they permit the identification or localization of the PA either because the label itself emits a detectable signal, or by virtue of its affinity for a label-specific partner which is detectable or becomes so by binding to, or otherwise reacting with, the label.
  • labels include, but are not limited to, radioactive isotopes, fluorescent tags, and proteinaceous tags.
  • the methods of identification and /or localization provided by the invention may be used in whole or as part of a diagnostic or research protocol.
  • the invention also provides preparative uses of the PAs.
  • one or more PAs can be used to bind and isolate proteins or other cellular factors that interact with polyamines.
  • An exemplar of such a method is the use of a PA to bind to a polyamine transporter and permit its isolation or purification.
  • These methods can be performed in solution, where interaction between a PA and a PA binding protein or factor results in a complex that may be subsequently isolated or purified from solution, or in solid phase, where a PA is immobilized and interactions between the PA and a PA binding protein or factor results in a complex of the protein or factor with the immobilized PA.
  • PAs analogs were synthesized in a parallel fashion starting from the orthogonally protected diamino containing amino acid starting materials.
  • the use of the 4-nitrophenyl activated ester L-Boc-Lys-(Cbz)-ONP in FIG. 1 provides an exemplary illustration of the synthetic process.
  • the active ester is added dropwise to a solution of 1.5 equivalents of polyamine in methanol to give a statistical mixture of unsubstituted, mono-substituted and di-substituted acyl polyamines.
  • the remaining free amino groups in the polyamine moiety are protected either as their t Boc or Cbz carbamates. Standard workup results in a completely protected crude product mixture.
  • the desired orthogonally-protected product is isolated in pure form by silica gel chromatography using standard organic solvents.
  • This purification process is based on separation of polyamine molecules with the remaining amino groups being fully protected, which provides a much more lipophilic product mixture that greatly facilitates the purification process.
  • the exemplary intermediates containing either 4 Boc groups or 4 Cbz groups in addition to the acyl functionality remained lipophilic enough to purify using standard solvents including a one to one mixture of ethyl acetate and hexanes containing various proportions of methanol (0 to 10%).
  • the approach provides two synthetic intermediates, one with 4 Boc and 1 Cbz carbamates and the other with 4 Cbz and 1 Boc carbamates. These intermediates allow the exposure of only one amino group, either the proximal ( ⁇ -) or distal ( ⁇ -), in a selective manner. It is also possible to modify this approach such that both amino groups are exposed for further modification.
  • the selective deprotection of either the proximal ( ⁇ -) or distal ( ⁇ -) amino group as shown in FIG. 1 may occur via catalytic hydrogenation or acid treatment, respectively.
  • the exposed amino groups were then acylated or alkylated with either an acyl chloride or sulfonyl chloride to produce Series I and II (see FIG.
  • the exposed amino groups may also be carboxylic acid activated with standard peptide coupling reagents such as DCC, PyPOP or HBTU (to produce Series III type PAs) or aldehydes under reductive amination conditions (to produce Series IV type PAs). Additional analogs are produced by reductive amination of the free amino precursor with one of the ketone reagents shown in Series V. Series VI analogs are produced via the reductive amination reaction using a free mono- or di-amine precursor and an excess of the carbonyl reagent that are shown in the Series VI chart.
  • An alternative method to produce these di-substituted tertiary amine-containing molecules is the conjugate addition of the selectively protected amine precursor to an ⁇ , ⁇ -unsaturated carbonyl compound or an ⁇ , ⁇ -unsaturated nitrile compound.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • LC-MS liquid chromatography-mass spectroscopy
  • All cell lines were obtained from ATCC (Manassas, Va.) and cultured in the recommended media, serum, and CO 2 concentration. Medias were obtained from Mediatech, Inc. (Herdon, Va.) and serums from Gibco BRL (Gaithersburg, Md.). 50 U/ml penicillin, 50 ⁇ g/ml streptomycin and 2 mM L-glutamine (all from Bio Whittaker, Walkersville, Md.) were included in all cultures. DFMO was obtained from Marion Merrell Dow (Cinncinati, Ohio). When cells were cultured with polyamines or ORI compounds, 1 mM aminoguanidine (AG; Sigma) was included to inhibit serum amine oxidase activity. IC 50 refers to the concentration of PA that results in 50% of maximum cell growth inhibition in the presence of PA alone.
  • Cells were plated in 96-well plates such that they would be in log growth for the duration of the assay. The day after plating, PAs were added to the cells, and growth, if any, permitted to continue for six days in the presence of 1 mM AG and 0.5 ⁇ M SPD to insure that any growth inhibition was not the result of depletion of external polyamines in the media. At the end of the six days, cell growth was measured by MTS/PMS dye assay (Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay; Promega, Madison, Wis.).
  • EC 50 represents the concentration of PA that resulted in 50% of maximum growth inhibition achievable in the presence of both DFMO (5 mM in all cell lines except MDA) and PA (at different concentrations depending in part on the cell line used) compared to controls.
  • IC 50 represents the concentration of PA that resulted in 50% maximum growth inhibition when used alone. Results are shown in Table 3 above.
  • Plasma samples from blood—remove 125-150 ⁇ l sample (optimally) into a microfuge tube and mix 1:1 with 0.4M perchloric acid. Vortex and spin down sample at 13000 rpm for 10 minutes in 5° C. centrifuge. Remove 200 ⁇ l supernatant for dansylation as described in dansylation protocol. Plasma samples as small as 25 ⁇ l may be analyzed (for this and the following discussion, any sample that does not yield 200 ⁇ l supernatant for dansylation may have its volume increased to 200 ⁇ l with perchloric acid for the dansylation protocol).
  • Tissues Keep samples on ice during preparation. Cut an approximately 100 mg piece from tissue sample and place into 15 ml conical tube. Add 1.2M perchloric acid in a 20:1 vol/weight ratio (i.e. 2 ml/100 mg). Homogenize tissue using a tissue grinder. Vortex sample and remove 1 ml into a microfuge tube. Spin at 13000 rpm for 10 minutes in 5° C. centrifuge. Remove 200 ⁇ l supernatant for dansylation as described in dansylation protocol.
  • Alltech C-18 maxi-prep cartridges are used, one for each sample dansylated, to clean any interfering reactions from the samples. This process also places the samples in methanol for application to the HPLC system.
  • Each cartridge is placed on a vacuum manifold and washed once with 3 ml MeOH followed by 3 ml H 2 O. Samples are then removed by 1 ml syringe from the glass vials and applied to the Alltech cartridges. Each cartridge is then washed with 10 ml H 2 O and dried 2 ⁇ with 30 cc syringe of air.
  • loop overfill is achieved by injecting 100 ⁇ l onto a 20 ⁇ l loop. Samples are kept at 4° C. until injection by a water cooled storage rack on the 231XL auto injector.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
US10/296,259 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use Ceased US6963010B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/047,297 USRE43327E1 (en) 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use
US10/296,259 US6963010B2 (en) 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use
US11/050,789 US20050176828A1 (en) 2001-01-08 2005-01-27 Hydrophobic polyamine analogs and methods for their use
US11/062,481 US7432302B2 (en) 2001-01-08 2005-02-23 Composition containing polyamine transport inhibitor and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26041501P 2001-01-08 2001-01-08
PCT/US2002/000347 WO2002053519A2 (fr) 2001-01-08 2002-01-08 Analogues de polyamine hydrophobe et procedes d'utilisation correspondants
US10/296,259 US6963010B2 (en) 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000347 A-371-Of-International WO2002053519A2 (fr) 2001-01-08 2002-01-08 Analogues de polyamine hydrophobe et procedes d'utilisation correspondants

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/047,297 Reissue USRE43327E1 (en) 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use
US11/050,789 Continuation US20050176828A1 (en) 2001-01-08 2005-01-27 Hydrophobic polyamine analogs and methods for their use
US11/062,481 Continuation-In-Part US7432302B2 (en) 2001-01-08 2005-02-23 Composition containing polyamine transport inhibitor and use thereof

Publications (2)

Publication Number Publication Date
US20030187276A1 US20030187276A1 (en) 2003-10-02
US6963010B2 true US6963010B2 (en) 2005-11-08

Family

ID=22989063

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/296,259 Ceased US6963010B2 (en) 2001-01-08 2002-01-08 Hydrophobic polyamine analogs and methods for their use
US11/050,789 Abandoned US20050176828A1 (en) 2001-01-08 2005-01-27 Hydrophobic polyamine analogs and methods for their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/050,789 Abandoned US20050176828A1 (en) 2001-01-08 2005-01-27 Hydrophobic polyamine analogs and methods for their use

Country Status (8)

Country Link
US (2) US6963010B2 (fr)
EP (1) EP1373185B1 (fr)
JP (1) JP4253503B2 (fr)
KR (1) KR100859929B1 (fr)
CN (1) CN100582084C (fr)
CA (1) CA2433807C (fr)
RU (1) RU2003124640A (fr)
WO (1) WO2002053519A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20050176828A1 (en) * 2001-01-08 2005-08-11 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US20050245615A1 (en) * 2001-01-08 2005-11-03 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
US20070203240A1 (en) * 2006-02-27 2007-08-30 The Procter & Gamble Company Personal care compositions and methods for regulating mammalian hair growth
EP3432914A4 (fr) * 2016-03-25 2019-11-13 Aminex Therapeutics, Inc. Polyamides biodisponibles
US11865095B2 (en) 2020-09-30 2024-01-09 Aminex Therapeutics, Inc. Combination drug substance of polyamine transport inhibitor and DFMO

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1448183A2 (fr) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Traitement de troubles neurodegeneratifs par modulation de la voie polyamine
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
EA200501518A1 (ru) * 2003-03-26 2006-04-28 Ресептикон Апс Применение соединений для профилактики лекарственно-индуцированной клеточной токсичности
RU2379315C2 (ru) * 2004-02-23 2010-01-20 Трастиз Оф Тафтс Колледж Ингибиторы дипептидилпептидазы iv
EP1765272B1 (fr) * 2004-06-14 2009-12-16 Unilever PLC Procede de diminution de la fabrication de sebum et du diametre des pores
US20060080150A1 (en) * 2004-09-30 2006-04-13 Southern Oregon Orthopedics, Inc. Whole-patient system for joint replacement care
US20060122279A1 (en) * 2004-11-12 2006-06-08 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
KR100682326B1 (ko) * 2005-01-14 2007-02-15 주식회사 엔젤금속 완충기능을 갖는 도어레버
US7199267B1 (en) * 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
KR100731122B1 (ko) * 2005-12-28 2007-06-22 동부일렉트로닉스 주식회사 씨모스 이미지 센서 및 그 제조방법
WO2011009039A2 (fr) 2009-07-16 2011-01-20 Pathologica Llc Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
EP2605799A4 (fr) * 2010-08-20 2014-02-26 Cerulean Pharma Inc Conjugués, particules, compositions et procédés associés
JP6370804B2 (ja) 2013-01-08 2018-08-08 パソロジカ エルエルシー 脱髄疾患の治療のための方法および組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
US5654287A (en) * 1990-12-13 1997-08-05 Merrell Phamaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N1 -bis[3-(ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
WO1997033560A1 (fr) * 1996-03-14 1997-09-18 Schering-Plough Healthcare Products, Inc. Composition et procede de bronzage sans soleil
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA853602B (en) * 1984-05-17 1985-12-24 Merrell Dow Pharma Method for the treatment of neoplasms
AU5957390A (en) * 1989-07-03 1991-02-06 New York University Use of polyamines as ionic-channel regulating agents
JPH05500357A (ja) * 1989-10-26 1993-01-28 ニューヨーク・ユニバーシティ イオンチャンネル調節剤としてのポリアミンの使用
US6646149B1 (en) * 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
JP4094230B2 (ja) * 1999-02-05 2008-06-04 メディクエスト セラピューティックス インク アンチザイムモジュレーターおよびその使用
CA2318004A1 (fr) * 1999-09-15 2001-03-15 Oridigm Corporation Analogues de polyamines nouveaux utilises comme agents therapeutiques et diagnostiques
RU2002128917A (ru) * 2000-03-24 2004-03-10 Медиквест Терапевтикс, Инк. (Us) Полиаминные аналоги в качестве цитотоксических агентов
EP1373185B1 (fr) * 2001-01-08 2017-03-01 Aminex Therapeutics, Inc. Analogues de polyamine hydrophobe et procedes d'utilisation correspondants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654287A (en) * 1990-12-13 1997-08-05 Merrell Phamaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N1 -bis[3-(ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
WO1997033560A1 (fr) * 1996-03-14 1997-09-18 Schering-Plough Healthcare Products, Inc. Composition et procede de bronzage sans soleil
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176828A1 (en) * 2001-01-08 2005-08-11 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US20050245615A1 (en) * 2001-01-08 2005-11-03 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
US7432302B2 (en) * 2001-01-08 2008-10-07 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20070203240A1 (en) * 2006-02-27 2007-08-30 The Procter & Gamble Company Personal care compositions and methods for regulating mammalian hair growth
EP3432914A4 (fr) * 2016-03-25 2019-11-13 Aminex Therapeutics, Inc. Polyamides biodisponibles
US10632145B2 (en) 2016-03-25 2020-04-28 Aminex Therapeutics, Inc. Bioavailable polyamines
EP3785706A1 (fr) 2016-03-25 2021-03-03 Aminex Therapeutics, Inc. Polyamides biodisponibles
US11395834B2 (en) 2016-03-25 2022-07-26 Aminex Therapeutics, Inc. Bioavailable polyamines
US11865095B2 (en) 2020-09-30 2024-01-09 Aminex Therapeutics, Inc. Combination drug substance of polyamine transport inhibitor and DFMO

Also Published As

Publication number Publication date
EP1373185B1 (fr) 2017-03-01
KR20030077568A (ko) 2003-10-01
CN100582084C (zh) 2010-01-20
JP4253503B2 (ja) 2009-04-15
CA2433807C (fr) 2012-04-24
RU2003124640A (ru) 2005-02-27
CA2433807A1 (fr) 2002-07-11
EP1373185A4 (fr) 2005-12-07
JP2004529082A (ja) 2004-09-24
US20050176828A1 (en) 2005-08-11
US20030187276A1 (en) 2003-10-02
WO2002053519A2 (fr) 2002-07-11
KR100859929B1 (ko) 2008-09-23
WO2002053519A3 (fr) 2003-03-13
EP1373185A2 (fr) 2004-01-02
CN1511137A (zh) 2004-07-07

Similar Documents

Publication Publication Date Title
US6963010B2 (en) Hydrophobic polyamine analogs and methods for their use
US7453011B2 (en) Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
US7160923B1 (en) Polyamine analogues as therapeutic and diagnostic agents
US20070066646A1 (en) Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
US20090124832A1 (en) Oligoamine compounds and derivatives thereof for cancer therapy
EP1159261B1 (fr) Modulateurs d'antizyme et leur utilisation
KR100851452B1 (ko) 치료제 및 진단제로서 새로운 폴리아민 유사체
US7132420B2 (en) Aspartic protease inhibitors
EP1085011A1 (fr) Polyamine analogues comme agents therapeutiques et diagnostiques
JP2004500406A (ja) 細胞毒性剤としてのポリアミン類似体
USRE43327E1 (en) Hydrophobic polyamine analogs and methods for their use
US7208528B1 (en) Polyamine analogues as therapeutic and diagnostic agents
AU2008201086B2 (en) Hydrophobic Polyamine Analogs and Methods for their Use
AU2002248311A1 (en) Hydrophobic polyamine analogs and methods for their use
US7432302B2 (en) Composition containing polyamine transport inhibitor and use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDIQUEST THERAPEUTICS, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURNS, MARK R.;GRAMINSKI, GERARD F.;BAINDUR, NAND;REEL/FRAME:014091/0897;SIGNING DATES FROM 20021021 TO 20021025

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: AMINEX THERAPEUTICS, INC.,WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDIQUEST THERAPEUTICS, INC.;REEL/FRAME:024120/0311

Effective date: 20100322

RF Reissue application filed

Effective date: 20110314

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载